US Bancorp Quote - USB-P | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NYSE
US Bancorp (USB-P) Share Price

US Bancorp (USB-P)

24.79

0.27

( 1.10% )

Updated: 06:29:17

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

24.79

Bid

-

Offer

-

Volume

56,770

24.48 Day's Range 24.83

0.00 52 Week Range 0.00

Market Cap

Previous Close

24.52

Open

24.61

Last Trade

Last Trade Time

06:28:01

Financial Volume

US$ 1,402,580

VWAP

24.71

Average Volume (3m)

-

Shares Outstanding

1,557,012,000

Dividend Yield

-

PE Ratio

15.89

Earnings Per Share (EPS)

3.26

Revenue

28.01B

Net Profit

5.08B

Sector

National Commercial Banks - Non Islamic

Industry

National Commercial Banks - Non Islamic

Website

www.usbank.com

Headquarters

Wilmington, Delaware, USA

Founded

-

US Bancorp is listed in the National Commercial Banks - Non Islamic sector of the New York Stock Exchange with ticker USB-P. The last closing price for US Bancorp was US$24.52. Over the last year, US Bancorp shares have traded in a share price range of US$ 0.00 to US$ 0.00.

US Bancorp currently has 1,557,012,000 shares in issue. The market capitalisation of US Bancorp is US$38.18 billion. US Bancorp has a price to earnings ratio (PE ratio) of 15.89.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	PR
4	0	0	0	0	0	0	0	PR
12	0	0	0	0	0	0	0	PR
26	0	0	0	0	0	0	0	PR
52	0	0	0	0	0	0	0	PR
156	0	0	0	0	0	0	0	PR
260	0	0	0	0	0	0	0	PR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
SRFMSurf Air Mobility Inc	US$ 2.7041 (31.91%)	622.38k
ODVOsisko Development Corporation	US$ 1.94 (31.08%)	1.72M
VATEINNOVATE Corp	US$ 4.76 (22.37%)	79.76k
CATOCato Corp	US$ 4.95 (-18.59%)	157.02k
KLCKindercare Learning Companies Inc	US$ 19.58 (-14.12%)	1.28M
CLCOCool Company LTD	US$ 9.39 (-11.75%)	1.84M
CPACopa Holdings SA	US$ 93.95 (-11.21%)	897.15k
DNMRDanimer Scientific Inc	US$ 5.0813 (-11.01%)	70.16k
CTVInnovid Corp	US$ 3.015 (86.11%)	50.79M
PLTRPalantir Technologies Inc	US$ 61.53 (-0.95%)	46.26M
SNOWSnowflake Inc	US$ 170.7193 (32.22%)	46.05M
NIONIO Inc	US$ 4.70 (1.08%)	41.9M
IONQIonQ Inc	US$ 33.01 (14.38%)	34.21M

manibiotech

manibiotech 3 minutes ago

However the data of current trial submitted for approval is not "in vitro"

payupdeadbeat

payupdeadbeat 3 minutes ago

It is clear that the "investment of a lifetime* message is not getting out. I hope the longs are not being hornscwaggled.

Craig305

Craig305 3 minutes ago

This is the highest day volume since June 2022.

Serpico2005

Serpico2005 3 minutes ago

HUGE revenue pouring in here, we won't be denied, won't be able the hold it down much longer.

delerious1

delerious1 3 minutes ago

Milling results soon yet some say that this stock is garbage etc have been here as long as me or longer so that would mean plenty of time to see the patterns and make some really good money....but I bet that they haven't....so it is a bit of a conundrum....why wouldn't they when obviously given the

ExtremelyBullishZig

ExtremelyBullishZig 3 minutes ago

No...all biotechs are up based on gene editing company success it move the index

richme

richme 3 minutes ago

Need to Curb Your Enthusiasm just because the share price jumped all the way to $0.0166 share price,
-$0.0015 day change. Isn't that great? We will be heading to Mars soon....no less in Elon Musk's rocket ship or to hell in ________ (add your own).

Quintessence

Quintessence 4 minutes ago

PDYNW - Nice move today! I will consider buying dips.

JRoon71

JRoon71 4 minutes ago

TC, I get that. I just meant that in looking at what Italy pays for other drugs, what Amarin wants for Vazkepa is substantially more than MOST drugs on the list.

I'm not talking about the cost to patients, but the cost to the government.

If Vazkepa cost $15 to sell to

dennisdave

dennisdave 4 minutes ago

BTW, the three companies with approved PD1 inhibitors, which is what the U.S. patent office tried to narrow the combo patent to, are:

Merck = Keytruda

Opdivo = Bristol

Libtayo = Regeneron.
Thanks very helpful.

attilathehunt

attilathehunt 4 minutes ago

1 buy of 20k will work the same as 2 buys of 10k on squeeze day, no?

NO!!!!!

On squeeze day your first buy order will be much much lower than all subsequent ones...

For example, on Squeeze day (approval) if your first early open trade gets executed at 1.0

bgATL

bgATL 5 minutes ago

Gaetz is out, my opinion has been he was never really going to be in the position, as it was cover to let him resign from the House before the severe reprimands which could have ruined his chances of a future career. Trump also could now argue he tried to put a pot friendly guy in the office and it

Pic 5 minutes ago

I wonder if .0011 is a good entry? Fishing time. 🎣

konshe

konshe 5 minutes ago

Strong buy at ask 0.0002, paint sell at bid 0.0001. 0.0002 2mm shares will be gone soon.

al44

al44 5 minutes ago

The world will become safer when the ‘adults in the room’ are… gone

By Jack Hellner

When Biden and his team of incompetents took over, the media cheered that finally the adults were back in the room; well thankfully, the “children” will be back soon and the U.S.

Real McCoy

Real McCoy 5 minutes ago

I think they think that announced participation in a hot industry segment should entitle them to valuation levels of those hot industry segment leaders. Despite ALWAYS having virtually no revenue.

KRISGO

KRISGO 5 minutes ago

Hello Dcaf7, based on the full abstract being released on Nov 25th, can the experts evaluate whether same-day dosing is effective and works better?

PennyMillions852

PennyMillions852 5 minutes ago

BID building here but...you KNOW what will come next......this is the type of chit that needs to stop for us to move up above .0003!

Hitman970

Hitman970 5 minutes ago

Why hasn't this historic moment made any mainstream press?
x / twitter and company generate PRs mean nothing.
You are repeating yourself over and over. Do you know Vic? You called him "benign" a while back.

CrashOverride

CrashOverride 5 minutes ago

If it was DCVax the 2016 paper would cite Liau or Prins as they are the leaders in the field of Dendritic-cell-based vaccines.

They had several papers published before 2016.

It doesn't so it isn't DCVax.

biotechinvestor1

biotechinvestor1 5 minutes ago

From another poster: “Evotec has already said no thanks. Wall Street said no thanks. When Halozyme management says ok forget about it, we go up $10. We are waiting Ms Helen.”

BamaBreeze

BamaBreeze 6 minutes ago

Can you bring in the update your referencing(please).

redspinelpinktopaz

redspinelpinktopaz 6 minutes ago

No. It seems all right to me.

glenn1919

glenn1919 6 minutes ago

TRNR....CISO....MULN.........................https://stockcharts.com/h-sc/ui?s=MULN&p=D&yr=0&mn=2&dy=12&id=p84071410134

WinstonCup

WinstonCup 6 minutes ago

Sometimes you make no sense.

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions